[
  {
    "ts": null,
    "headline": "These Are The Worst 25 Stocks to Own in February",
    "summary": "Biogen stock tends to disappoint in February",
    "url": "https://finnhub.io/api/news?id=4ea5354df6101b8335eae9361e6c50048afe8d2d0303349a30e64ba88dde8e64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770148649,
      "headline": "These Are The Worst 25 Stocks to Own in February",
      "id": 138345699,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen stock tends to disappoint in February",
      "url": "https://finnhub.io/api/news?id=4ea5354df6101b8335eae9361e6c50048afe8d2d0303349a30e64ba88dde8e64"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=814a226bc754bdb1c308912f3c074d8bf39476fc6742320e7bdb458a4dc460e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130813,
      "headline": "Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 138344458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=814a226bc754bdb1c308912f3c074d8bf39476fc6742320e7bdb458a4dc460e9"
    }
  },
  {
    "ts": null,
    "headline": "New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings",
    "summary": "Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.",
    "url": "https://finnhub.io/api/news?id=97013c3399ae4454f60a2ef7629b331ac983fee8d6b0dcd7c332d70683a53752",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770123360,
      "headline": "New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings",
      "id": 138342021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.",
      "url": "https://finnhub.io/api/news?id=97013c3399ae4454f60a2ef7629b331ac983fee8d6b0dcd7c332d70683a53752"
    }
  },
  {
    "ts": null,
    "headline": "1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky",
    "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
    "url": "https://finnhub.io/api/news?id=83fac3e3ab0c165d8951ca7bf215374fedf7268b9cde6cf1bc71f62291c9d88e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770093164,
      "headline": "1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky",
      "id": 138340122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.",
      "url": "https://finnhub.io/api/news?id=83fac3e3ab0c165d8951ca7bf215374fedf7268b9cde6cf1bc71f62291c9d88e"
    }
  },
  {
    "ts": null,
    "headline": "C4 Therapeutics, Inc. (CCCC): A Bull Case Theory",
    "summary": "We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein […]",
    "url": "https://finnhub.io/api/news?id=e054ac2ebf2e55b84a09217a33f1d651846cd3461309461c2408fd2d3c07e2c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770083666,
      "headline": "C4 Therapeutics, Inc. (CCCC): A Bull Case Theory",
      "id": 138338023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC. C4 Therapeutics, Inc.’s share was trading at $1.9600 as of January 29th. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein […]",
      "url": "https://finnhub.io/api/news?id=e054ac2ebf2e55b84a09217a33f1d651846cd3461309461c2408fd2d3c07e2c4"
    }
  }
]